Clinical trials have shown that sonidegib is effective in shrinking tumors and managing symptoms in patients with laBCC. In the BOLT (Basal cell carcinoma Outcomes with LDE225 Treatment) study, a significant proportion of patients experienced a reduction in tumor size, with some achieving complete remission. However, the efficacy can vary among individuals, and ongoing monitoring is essential to assess the treatment response.
